ArticleJournal of cytology
Pancreatic Cytology Precision: A Comparative Lens on Papanicolaou Society of Cytopathology and World Health Organization Reporting System.
Article in Journal of cytology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Context: Pancreatic lesions range from benign cystic to premalignant and frankly malignant. The Papanicolaou Society of Cytopathology (PSC) was established in 2014 for pancreaticobiliary cytology, with a six-tiered system. Recently, the World Health Organization (WHO) proposed a reporting system for pancreaticobiliary cytopathology. Aims: This study aimed to apply PSC and WHO systems to pancreatic cytology samples and compare their risk assessment. Materials and Methods: The Institutional Hospital Information System was searched for all pancreatic endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA), transabdominal ultrasound-guided FNA (TUS-FNA), and pancreatic fluid cytology samples from January 2016 to April 2025, and cases were reassigned as per the PSC and WHO diagnostic categories by two cytopathologists. Risk of malignancy (ROM) in each diagnostic category was assessed using available histopathological, clinical, radiological, biochemical, and follow-up data. Results: Of 281 pancreatic cytology cases via EUS (64.1%) and TUS-FNA (35.9%), 197 had complete follow-up records. The ROM for the PSC categories I-VI was 58.3%, 0%, 75%, 64.7%, 100%, and 100%. For WHO system categories I-IV, VI-VII, ROM values were 66.7%, 0%, 75%, 0%, 100%, and 100%. These findings indicate that the WHO system offers more effective risk stratification. Furthermore, compared with the PSC system, the WHO system showed an increase in sensitivity (89.2% vs. 81.4%), negative predictive value (NPV; 82.7% vs. 73.9%), and accuracy (92.9% vs. 87.8%), while specificity and positive predictive value (PPV) stayed consistent at 100%. Conclusion: The WHO reporting system for pancreatic cytology offers superior risk categorization, sensitivity, NPV, and accuracy compared with the PSC system, while maintaining comparable specificity and PPV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.